At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 238 enrolled
Drug / intervention
Daclatasvir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
In Brief
A Phase 3 clinical trial evaluating Daclatasvir and Sofosbuvir for Hepatitis C. Completed, enrolled 238 participants across 37 sites.
Detailed Summary
A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartFeb 2014
Primary CompletionOct 2014
Study CompletionJan 2015
TodayJul 2026
First PostedJan 10, 2014
Enrollment StartFeb 1, 2014
Primary CompletionOct 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.5 years ago
Interventions
Daclatasvirdrug
Sofosbuvirdrug